Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JPWA Compares Traceability Regulations to Prevent Distribution of Counterfeit Drugs in Japan, US, EU
November 13, 2019
- JMA Chides MHLW for Information Provisioning on Cefazolin Shortage
October 18, 2019
- Obituary: Harrison Cook, Eli Lilly
October 15, 2019
- Japan Pharmacist Group Taps Ex-Bureaucrat Isobe for Director Post
October 11, 2019
- Patients Want Access to Innovative Drugs Even If Expensive: PhRMA Survey
October 7, 2019
- PhRMA Chair Urges Japan to Rectify PMP Criteria, Narrow Definition of Innovation
October 4, 2019
- Japan Doctors’ Group to Issue Statement to Push for HPV Vaccines by FY2019-End
October 3, 2019
- Generic Industry Pondering Specific Proposal to Address Unreasonable Price Rises
October 2, 2019
- Generic Association Focuses on Pre-symptomatic/Preventive Care and Overseas Expansion in “Post-80% Era”
October 2, 2019
- Generic Use Rate at 75.8% in April-June: JGA
September 27, 2019
- Janssen’s Chris Hourigan Succeeds Jonsson as PhRMA Japan Chair
September 26, 2019
- EFPIA Japan Stresses Safety First and Need for Doctors’ Support on Delisting of OTC-Like Drugs, Notes Good Examples Overseas
September 25, 2019
- FPMAJ Sets Up New Taskforce to Promote Access to Japanese Drugs in Asia
September 24, 2019
- Nearly 80% of Japanese Support Insurance Coverage for High-Priced Drugs: Nonprofit Survey
September 18, 2019
- Strengthening Regulatory Science Will Accelerate Innovation in Drug Discovery: JPMA President
September 10, 2019
- Bristol-Myers CEO Caforio Named New PhRMA Chair, Tokyo Visit in October
September 6, 2019
- Number of Sales Reps in Japan Falls Below 60,000 in FY2018, Records 5 Consecutive Years of Decline
August 30, 2019
- Japan Doctors’ Group Raps Payer Proposal to Scrap Coverage for Pollen Allergy Drugs
August 29, 2019
- Kenporen Proposes Excluding OTC-Like Pollinosis Drugs from Health Coverage, Expecting Annual Savings of 60 Billion Yen
August 26, 2019
- Lab Test Group Seeks Better Reimbursement Rules for Cancer Gene Panel Testing
August 21, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…